• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Galapagos NV

    2/14/25 8:00:23 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Galapagos NV

    (Name of Issuer)


    Ordinary Shares, no par value

    (Title of Class of Securities)


    36315X101

    (CUSIP Number)


    Kevin Tang
    4747 Executive Drive, Suite 210
    San Diego, CA, 92121
    858-200-3830

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/07/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    TANG CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,910,525.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,910,525.00
    11Aggregate amount beneficially owned by each reporting person

    4,910,525.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    7.5 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Tang Capital Management, LLC ("TCM") beneficially owns 4,910,525 of the Issuer's Ordinary Shares, which consists of: (i) 966,119 Ordinary Shares, (ii) 2,544,406 American Depository Receipts ("ADRs"), each of which represents one Ordinary Share of the Issuer and (iii) 1,400,000 ADRs that the Reporting Persons have a right to purchase pursuant to call option contracts. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III") and Kevin Tang. The percentages used herein are based on 65,897,071 Ordinary Shares outstanding as of December 31, 2024, as set forth in the Financials section of the Issuer's website.


    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    KEVIN TANG
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,910,525.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,910,525.00
    11Aggregate amount beneficially owned by each reporting person

    4,910,525.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    7.5 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Kevin Tang beneficially owns 4,910,525 of the Issuer's Ordinary Shares, which consists of: (i) 966,119 Ordinary Shares, (ii) 2,544,406 ADRs, each of which represents one Ordinary Share of the Issuer and (iii) 1,400,000 ADRs that the Reporting Persons have a right to purchase pursuant to call option contracts. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III and TCM.


    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    TANG CAPITAL PARTNERS, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,723,147.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,723,147.00
    11Aggregate amount beneficially owned by each reporting person

    2,723,147.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    TCP beneficially owns 2,723,147 of the Issuer's Ordinary Shares, which consists of: (i) 548,443 Ordinary Shares, (ii) 1,387,304 ADRs, each of which represents one Ordinary Share of the Issuer and (iii) 787,400 ADRs that TCP has a right to purchase pursuant to call option contracts. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    TANG CAPITAL PARTNERS INTERNATIONAL, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,962,418.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,962,418.00
    11Aggregate amount beneficially owned by each reporting person

    1,962,418.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.0 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    TCPI beneficially owns 1,962,418 of the Issuer's Ordinary Shares, which consists of: (i) 417,676 Ordinary Shares, (ii) 932,142 ADRs, each of which represents one Ordinary Share of the Issuer and (iii) 612,600 ADRs that TCPI has a right to purchase pursuant to call option contracts. TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    TANG CAPITAL PARTNERS III, INC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    224,960.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    224,960.00
    11Aggregate amount beneficially owned by each reporting person

    224,960.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.3 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    TCP III beneficially owns 224,960 of the Issuer's ADRs, each of which represents one Ordinary Share of the Issuer. TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    TANG CAPITAL PARTNERS IV, INC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    36315X101


    1 Name of reporting person

    CONCENTRA BIOSCIENCES, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, no par value
    (b)Name of Issuer:

    Galapagos NV
    (c)Address of Issuer's Principal Executive Offices:

    GEN DE WITTELAAN L11 A3, 2800 MECHELEN, BELGIUM , 00000.
    Item 2.Identity and Background
    (a)
    This Statement is filed by TCM, a Delaware limited liability company that is the general partner of TCP and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; TCP III, a Nevada corporation that is indirectly wholly owned by TCP; Tang Capital Partners IV, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP IV"); and Concentra Biosciences, LLC, a Delaware limited liability company ("Concentra" and, collectively with TCM, Kevin Tang, TCP, TCPI, TCP III and TCP IV, the "Reporting Persons").
    (b)
    The address of TCM, Kevin Tang, TCP, TCPI and Concentra is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 5955 Edmond Street, Las Vegas, NV 89118.
    (c)
    Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. Kevin Tang is the Chief Executive Officer of Concentra.
    (d)
    During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    See Item 2(a) above.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Shares and options were acquired with approximately $93.9 million of working capital set aside by TCP, TCPI and TCP III for the general purpose of investing. TCP, TCPI and TCP III maintain commingled margin accounts with various financial institutions, which may extend margin credit to TCP, TCPI and TCP III as and when required, to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts. The margin accounts may from time to time have debit balances. Since multiple different securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Shares reported herein.
    Item 4.Purpose of Transaction
     
    The Reporting Persons purchased the Shares and options reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage in discussions with the Issuer and its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or propose changes to the Issuer's operations or governance. There can be no certainty as to whether discussions with the Issuer will occur, the outcome of any such discussions or whether the Reporting Persons will take any actions relating to the Issuer. Subject to applicable law and regulation, the Reporting Persons may modify their ownership of the Shares or options, including acquiring additional Shares or options or disposing of some or all of the Shares or options beneficially owned by them. Such actions may be based on the Reporting Persons' assessment of the Issuer's operations and prospects, prevailing market conditions or other investment considerations.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 4,910,525 of the Issuer's Shares, representing 7.5% of the outstanding Shares.
    (b)
    See item 5(a) above.
    (c)
    Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Shares that were effected during the past 60 days by the Reporting Persons.
    (d)
    No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Shares beneficially owned by the Reporting Persons.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The Reporting Persons have potential obligations to purchase 1,043,500 of the Issuer's Shares pursuant to put option contracts that expire on February 21, 2025 with a strike price of $25. The Reporting Persons have the right to purchase 1,400,000 of the Issuer's Shares pursuant to call option contracts that expire on February 21, 2025 with a strike price of $25. The Reporting Persons have potential obligations to sell 200,000 of the Issuer's Shares pursuant to call option contracts that expire on April 17, 2025 with a strike price of $30.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1: Joint Filing Agreement by and among the Reporting Persons. Exhibit 2: Schedule A: Transactions during the past 60 days.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TANG CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager
    Date:02/14/2025
     
    KEVIN TANG
     
    Signature:/s/ Kevin Tang
    Name/Title:Self
    Date:02/14/2025
     
    TANG CAPITAL PARTNERS, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:02/14/2025
     
    TANG CAPITAL PARTNERS INTERNATIONAL, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:02/14/2025
     
    TANG CAPITAL PARTNERS III, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:02/14/2025
     
    TANG CAPITAL PARTNERS IV, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:02/14/2025
     
    CONCENTRA BIOSCIENCES, LLC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:02/14/2025
    Get the next $GLPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    1/5/26 4:57:09 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    12/18/25 4:32:37 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Galapagos NV

    S-8 - GALAPAGOS NV (0001421876) (Filer)

    12/10/25 4:10:54 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

    Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co

    1/5/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

    GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile was consistent with previous studies with GLPG3667 Galapagos will evaluate all strategic alternatives, including resumption of its partnering process, to accelerate further development of GLPG3667 in dermatomyositis and potentially other severe auto-immune indic

    12/18/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

    High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. "The new and updated results from the Phase 2 ATALANTA-1 study demonstrate that GLPG5101 offers timely treatment with low rates of high-grade toxic

    12/8/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

    New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-

    10/30/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

    Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said

    7/23/25 4:03:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

    Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co

    1/5/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

    First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

    4/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care